Data Presented at the Annual Meeting of the Asian Academy of Neurology Specialists Offers Additional Support for Plasma Exchange.
Braincure-Biotech.com reports additional findings from a study which shows that plasma exchange accelerates the removal of relapsing forms of MS from blood serum in patients.
Taipei; 31, December 2015: Braincure-Biotech.com (ISIN:TW0001327872) reports additional findings from a study which shows that plasma exchange accelerates the removal of relapsing forms of MS (multiple sclerosis) from blood serum in patients and may help improve central nervous system immune response based on an in vitro model. The data was presented today at the Annual Meeting of the Asian Academy of Neurology Specialists (AANS). Plasma exchange is one of several research efforts the companies have underway to learn more about potential interventions or treatments for progressive multifocal leukoencephalopathy (PML).
"The goal of these studies is to evaluate the value of plasma exchange in patients who may develop PML. The data are encouraging as they show that removal of relapsing forms of MS through plasma exchange may be a potential intervention to rapidly clear relapsing forms of MS and restore immune function when clinically appropriate,” said the study’s lead author, Liao Ming, MD, Head of Department of Neurology at Braincure Biotech.
The multicenter exploratory study involving 16 patients with relapsing-remitting multiple sclerosis, designed to explore whether plasma exchange could significantly reduce the concentration of relapsing forms of MS in blood serum and alpha 4-integrin receptor saturation. Plasma exchange is an established method of removing large molecules from the body’s blood circulation. Based on the study findings, plasma exchange was effective at accelerating the normal decline of relapsing forms of MS serum concentrations.
About Braincure Biotech:
Braincure-Biotech.com is a state-of-the-art technology research company that uses discoveries in neuroimmunolgy and human genetics to develop novel therapeutics for Alzheimer’s disease, other forms of dementia, and mechanistically similar disorders. Braincure Biotech’s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. The goal of the firm is to discover and develop novel, disease modifying therapies for dementia and mechanistically similar disorders. The highly professional and acclaimed team of scientists maintains an innovative and motivating environment in which every employee has the possibility to contribute to our joint success and to grow individually.
For Media Contact:
Address: Taipei Far Eastern Plaza
No. 207, Section 2
Dun Hua South Road,
Taipei 106, Taiwan